沃森生物(300142.SZ)一季度預虧1800萬–2300萬元 同比盈轉虧
格隆匯3月20日丨沃森生物(300142.SZ)公佈,預計2020年第一季度歸屬於上市公司股東的淨虧損1800萬元–2300萬元,上年同期盈利3873.32萬元。
公司是專業從事人用疫苗研發、生產與銷售的生物製藥企業,主營業務以生產銷售自主疫苗產品為主,2019年自主疫苗銷售收入佔營業收入比例達97%。2020年1季度,新型冠狀病毒感染肺炎疫情廣泛波及影響絕大部分地區和行業,全國各省、市相繼啟動了重大突發公共衞生事件一級響應,全國各地均採取多種手段防控疫情
。疫情期間,疫苗的准入和管理機構及各省、市、縣(區)級疾病預防控制中心全力投入抗疫工作,絕大部分疫苗接種門診因新冠疫情防控要求而暫停接種疫苗;受交通物流停運影響,疫苗產品配送也碰到很大的困難。近期境外新型冠狀病毒感染肺炎疫情形勢持續惡化,公司國際銷售業務面臨較大挑戰,如境外疫情嚴峻形勢持續,公司還存在部分進口生產原輔材料採購受影響的風險。
疫情給公司2020年第一季度銷售造成較大影響,收入和利潤均出現大幅下滑,導致歸屬於上市公司股東的淨利潤較上年同期下降並出現虧損。公司將對國內和境外新型冠狀病毒感染肺炎疫情進行密切跟蹤和評估,及時調整各項經營安排,採取多種措施保障生產經營工作安全有序開展,努力降低疫情對公司生產經營的不利影響。
報告期內,公司預計非經常性損益影響歸屬於上市公司股東的淨利潤約190萬元,上年同期為147.08萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.